Highlights

  • Cambium Bio Limited (ASX:CMB) was unchanged at A$0.405 on 13 July 2026, a market capitalisation of roughly A$11.1 million.
  • Cambium Bio is the entity formerly listed as Regeneus; it took its current name and ticker after a merger with US-based Cambium and a backdoor-style listing.
  • Its lead programme is Elate Ocular (referenced as CAM-101), a biologic eye drop for dry eye disease, advancing through the Phase 3 CAMOMILE-2 and CAMOMILE-3 trials.
  • The US FDA is reported to have aligned on a pathway where a single pivotal Phase 3 study plus confirmatory evidence could support a future Biologics License Application (BLA).
  • The 13 July 2026 flat close reflects a thinly traded micro-cap; investors face clinical, funding and liquidity risk, with a Phase 3 readout the key catalyst.

Cambium Bio Limited (ASX:CMB) is a small Australian regenerative-medicine company that, on 13 July 2026, did not move. According to the market snapshot dated 13 July 2026, the stock was unchanged at A$0.405, a market capitalisation of roughly A$11.1 million; those ASX prices are delayed by at least 20 minutes and may since have changed. What makes Cambium worth watching is not its day-to-day price but the stage its lead programme has reached: a Phase 3 clinical effort in dry eye disease that could, over time, define the company's value.

What happened to Cambium Bio shares?

On 13 July 2026, Cambium Bio (ASX:CMB) closed the snapshot period unchanged at A$0.405 — a 0.00% move. For a low-volume micro-cap, an unchanged session is unremarkable and reflects an absence of trading pressure rather than any judgement about prospects. Its roughly A$11.1 million market capitalisation is among the smaller ASX biotechnology names, and because the stock is thinly traded its price can be static and then move sharply around news. The flat close is a neutral data point; snapshot figures may have since changed, and investors should rely on official disclosures.

Was there a verified catalyst?

No company announcement dated 13 July 2026 was identified that would move Cambium's shares, and the price was unchanged. The most relevant developments in the verified record concern the Phase 3 CAMOMILE programme and its funding, both of which pre-date the snapshot. For a clinical-stage micro-cap, the meaningful catalysts are typically clinical and regulatory: progress of the Phase 3 trials and, ultimately, a top-line readout. On 13 July 2026 itself there was no such catalyst; readers should rely on Cambium's official ASX announcements for confirmed developments.

What does Cambium Bio (ASX:CMB) do?

Cambium Bio is an Australian regenerative-medicine company developing biologic therapies, with a lead focus on ophthalmology. It is the entity previously listed on the ASX as Regeneus; following a merger with US-headquartered Cambium and a backdoor-style listing, it adopted the Cambium Bio name and the ticker CMB.

The headline asset is Elate Ocular, a biologic eye drop for dry eye disease — a common, often chronic condition of the ocular surface — positioned as regenerative, aimed at the underlying biology rather than only symptoms. Cambium also retains platform assets from its Regeneus heritage, including a stem-cell technology (Progenza) and a wound-healing programme (Sygenus). These are earlier-stage optionality; the near-term investment case centres on the dry-eye programme.

Key products, technologies and clinical programs

Cambium's lead programme is Elate Ocular (referenced as CAM-101), developed for dry eye disease (keratoconjunctivitis sicca). The company has described a Phase 3 plan comprising two identically designed multi-regional trials, CAMOMILE-2 and CAMOMILE-3, with co-primary endpoints in the signs (such as corneal staining) and symptoms (such as eye discomfort) of disease, designed to support a future Biologics License Application (BLA) if successful. This is a genuine late-stage clinical effort, distinguishing Cambium from many pre-clinical micro-caps. However, Phase 3 is the most demanding and expensive stage, and success is not assured even after positive earlier data. The broader platform assets remain earlier-stage and are not the primary driver of the current investment case.

Clinical-development position

Cambium is a late-stage clinical company by virtue of its Elate Ocular programme, positioned in Phase 3 — a more advanced position than most ASX micro-cap biotechs occupy. But being in Phase 3 is not the same as having succeeded: the CAMOMILE-2 and CAMOMILE-3 trials must still meet their co-primary endpoints to support a BLA, and dry-eye disease has a history of trials failing to separate clearly from placebo. Cambium's value hinges substantially on these results, subject to clinical and regulatory risk.

Regulatory and commercial pathway

Cambium's regulatory strategy centres on the US FDA, which the company reports aligned on a pathway under which a single well-controlled pivotal Phase 3 study, together with confirmatory evidence, could support a future BLA for Elate Ocular. This is potentially capital-efficient, but a BLA is a submission, not an approval, and pathway alignment does not guarantee the trials will succeed. Commercially, dry eye disease is a large market with multiple approved therapies, so a new entrant must demonstrate differentiated benefit and would face substantial commercialisation costs. As a small company, Cambium's realistic route to full commercialisation may involve partnering or licensing — prospective outcomes that depend first on clinical success.

Latest financial position

Cambium is a pre-revenue, clinical-stage company that funds its development through capital raisings. In the verified record, it completed a raise of about A$3.0 million, directed primarily toward advancing Elate Ocular through its Phase 3 trials. This is modest relative to the cost of running two Phase 3 studies; for a company with a roughly A$11.1 million market capitalisation on 13 July 2026, the gap between available funding and the full cost of a Phase 3 programme is central. Cambium is expected to incur operating losses and will likely need additional funding — an inherent source of dilution risk. Investors should rely on Cambium's official quarterly (Appendix 4C) and annual reports for precise, period-dated figures in Australian dollars.

Market opportunity

Dry eye disease is a large addressable market: a common, often chronic condition where demand for effective treatments is significant, supporting a sizeable opportunity for therapies that can demonstrate meaningful benefit. The counterweight is competition and evidentiary demands — the market already includes several approved products, and prescribers set a high bar for new entrants. The opportunity described here is potential rather than realised, becoming commercially relevant only if the CAMOMILE trials succeed and a BLA is ultimately approved.

Recent official announcements

The most relevant verified developments in Cambium's recent record are its corporate formation — the merger with US-based Cambium and the name change from Regeneus to Cambium Bio (CMB) — its FDA-aligned Phase 3 pathway for Elate Ocular, the design of the CAMOMILE-2 and CAMOMILE-3 trials, and a capital raising of about A$3.0 million to fund that programme. Beyond these items, this article does not report unverified milestones; because trial timelines can shift, investors should consult Cambium's official ASX announcements and periodic reports directly.

Potential positive considerations

Several features may appeal to investors comfortable with high risk. Most notably, Cambium's lead asset is at Phase 3 — a more advanced stage than most ASX micro-cap biotechs — targeting the large dry-eye market, with a reported FDA-aligned pathway under which a single pivotal study plus confirmatory evidence could support a BLA. Cambium also secured funding to advance the programme and retains additional platform assets providing optionality, and a positive Phase 3 readout could, given the company's small size, be a significant re-rating event. Each is a consideration rather than a conclusion, and none removes the substantial clinical and funding risk.

Main risks and uncertainties

The risks are substantial. Cambium's value is heavily concentrated in a single late-stage programme, Elate Ocular, whose Phase 3 trials must succeed to support registration; dry-eye trials are notoriously difficult, with many candidates failing to separate from placebo. Funding and dilution risk are central: a A$3.0 million raise is modest against the cost of two Phase 3 studies, so Cambium is likely to need further capital, which could dilute shareholders materially, and a negative trial outcome could severely impair its value. Liquidity and volatility risk are meaningful in a thinly traded micro-cap, and an FDA-aligned pathway is not an approval. This article does not constitute financial or medical advice.

What investors may watch next

Investors following Cambium Bio (ASX:CMB) may focus above all on the Phase 3 CAMOMILE programme — the enrolment, conduct and, ultimately, the top-line readout of the CAMOMILE-2 and CAMOMILE-3 trials, which would be the most important catalyst. The cash position and burn rate — disclosed in quarterly Appendix 4C — will indicate how much runway the recent raise provides, and any licensing or partnering announcement could materially change the investment case. Given the stock's thin liquidity, market participants may treat both flat sessions — like that on 13 July 2026 — and sharp moves with appropriate context, subject to clinical, regulatory and financing outcomes.

A balanced view on Cambium Bio (ASX:CMB)

Cambium Bio (ASX:CMB) is a repositioned regenerative-medicine micro-cap whose flat 13 July 2026 close, at A$0.405, reflects thin trading rather than any specific news. What distinguishes it from many peers is the advanced stage of its lead asset: Elate Ocular is in Phase 3 for dry eye disease, with an FDA-aligned registration pathway. The constructive case rests on that late-stage position, the large dry-eye market, a potentially efficient BLA pathway, and recent funding; the cautious case reflects heavy concentration in a single programme, the well-documented difficulty of dry-eye trials, a funding gap relative to Phase 3 costs, and the liquidity constraints of a small stock. Cambium's outcome depends substantially on the CAMOMILE trial results, which are not yet known. Nothing here is financial or medical advice.